Stockscreener 앱 받기
158.44
0.37%
0.59
시간 외 거래:
158.44
전일 마감가:
$157.85
열려 있는:
$157.15
하루 거래량:
871.14K
Relative Volume:
0.61
시가총액:
$12.80B
수익:
$8.19B
순이익/손실:
$758.19M
주가수익비율:
17.26
EPS:
9.18
순현금흐름:
$1.06B
1주 성능:
-4.81%
1개월 성능:
+4.53%
6개월 성능:
-18.10%
1년 성능:
-49.39%
1일 변동 폭
$154.97
$159.16
1주일 범위
$154.69
$168.16
52주 변동 폭
$125.10
$328.35
Icon Plc Stock (ICLR) Company Profile
ICLR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
158.44 | 12.09B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
460.72 | 169.53B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
200.56 | 139.75B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
658.06 | 49.94B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
114.62 | 32.16B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
179.86 | 30.17B | 15.50B | 1.33B | 2.16B | 7.34 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-24 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-04-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-04-14 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-04-10 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | 개시 | Redburn Atlantic | Neutral |
| 2024-09-18 | 개시 | Leerink Partners | Outperform |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2023-12-15 | 개시 | Truist | Buy |
| 2023-09-13 | 개시 | TD Cowen | Outperform |
| 2023-01-17 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-01-13 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-11-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-09-07 | 개시 | UBS | Buy |
| 2022-08-25 | 개시 | Credit Suisse | Neutral |
| 2022-05-24 | 개시 | Guggenheim | Buy |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2021-09-27 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-07-23 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-14 | 개시 | Citigroup | Neutral |
| 2021-04-13 | 재개 | BofA Securities | Neutral |
| 2021-04-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | 개시 | Barclays | Equal Weight |
| 2021-03-01 | 업그레이드 | UBS | Neutral → Buy |
| 2021-02-26 | 업그레이드 | Truist | Hold → Buy |
| 2020-07-24 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Hold |
| 2020-01-27 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-09-23 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | 업그레이드 | UBS | Sell → Neutral |
| 2019-01-25 | 업그레이드 | Mizuho | Neutral → Buy |
| 2018-10-26 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-10-09 | 개시 | UBS | Sell |
| 2018-04-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-15 | 재확인 | Mizuho | Neutral |
| 2018-01-19 | 개시 | Evercore ISI | Outperform |
| 2017-10-27 | 재확인 | Barclays | Equal Weight |
| 2017-09-11 | 개시 | BofA/Merrill | Buy |
| 2017-07-31 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-07-27 | 재확인 | Mizuho | Neutral |
| 2017-06-29 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Icon Plc 주식(ICLR)의 최신 뉴스
Fund Update: First Pacific Advisors, LP added 417,173 shares of ICON PLC ($ICLR) to their portfolio - Quiver Quantitative
ICON Plc’s Earnings Call: Balancing Achievements and Challenges - TipRanks
ICON plc: Initiation of Coverage- Capitalizing On Opportunities in China, A Critical Growth Market! - smartkarma.com
ICON Plc's Q2 Earnings Call: Balancing Growth and Challenges - AInvest
Deutsche Bank Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $210 - 富途牛牛
Leerink Partners Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $240 - 富途牛牛
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape By Investing.com - Investing.com India
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape - Investing.com
ICON's Intrinsic Value Estimated at $278, 33% Undervalued by Current Share Price - AInvest
Icon price target raised to $225 from $173 at Mizuho - TipRanks
ICON plc Q2 2025 Financial Results: Revenue Up 0.8%, Net Income Rises 30.7% - AInvest
UBS Raises Icon PLC Price Target to $240, Maintains 'Buy' Rating - AInvest
Icon PLC (ICLR) Sees Price Target Boost Amid Stable Booking Trends - AInvest
Icon PLC (ICLR) Q2 Report: Barclays Raises Price Target to $180, Maintains Equal Weight Rating - AInvest
ICON plc Reports Strong Q2 2025 Financial Results - The Globe and Mail
ICON plc Expands Share Repurchase Program and Resumes COVID Vaccine Study - The Globe and Mail
ICON plcOrdinary Shares (Nasdaq:ICLR) Stock Quote - FinancialContent
Evercore Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $240 - 富途牛牛
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $209 to $240 - 富途牛牛
Icon PLC (ICLR) Q2 2025 Earnings Call Highlights: Navigating Cha - GuruFocus
Icon plc's Shares Surge 17.2% Amid Investor Optimism - AInvest
Icon Plc Announces Kedrion IVIg 10% Study for Chronic ITP: Market Implications - AInvest
ICON Expects $8B in Revenue for Full Year, Driven by Biotech Wins and Pharma Partnerships - AInvest
ICON plc Announces Successful AGM Resolutions - The Globe and Mail
ICON Stock Surge: Future Safe or Risky? - StocksToTrade
ICON’s Unexpected Surge: What’s Behind the Jump? - timothysykes.com
ICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma Recovery - Benzinga
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $170 to $224 - 富途牛牛
Icon plc (ICLR) Shares Surge Over 17% Amid Investor Optimism | ICLR Stock News - GuruFocus
Icon Plc’s New Study on Kedrion IVIg 10% for Chronic ITP: What Investors Need to Know - TipRanks
ICON’s Earnings Beat and Strategic Moves: A Market Outlook - StocksToTrade
RPM International Posts Better-Than-Expected Earnings, Joins ICON, MaxLinear, Nasdaq And Other Big Stocks Moving Higher On ThursdayArrive AI (NASDAQ:ARAI), ASGN (NYSE:ASGN) - Benzinga
Growth or Bubble? Decoding the Rapid Rise of ICLR Stock - StocksToTrade
Icon PLC Q2 Earnings Exceed Projections with $183 Million ProfitNews and Statistics - IndexBox
S&P 500 Futures Climb in Premarket Trading; West Pharmaceutical Svcs, Icon PLC Lead - Barron's
ICON: Lower Guidance Downside & Expanded Repurchase Plan (ICLR) - Seeking Alpha
Icon PLC: Q2 Earnings Snapshot - CTPost
ICON plc Reports Strong Q2 2025 Financial Results and Updates Guidance - The Globe and Mail
ICON Announces Results of Annual General Meeting - BioSpace
William Blair Maintains Icon PLC(ICLR.US) With Buy Rating - 富途牛牛
ICON PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Icon PLC (ICLR) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
ICON PLC earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
SUI Insider Grant: President Gets 4,788 Restricted Shares at $125.06 | ICLR SEC FilingForm 6-K - Stock Titan
ICON Reports Second Quarter 2025 Results | ICLR Stock News - GuruFocus
ICON's Resilience in a Turbulent Market: A Case for Strategic Investment - AInvest
ICON Announces Results of Annual General Meeting | ICLR Stock News - GuruFocus
ICON Clinical Research Earnings Soar 31% as Business Wins Hit $3B, Expands $1B Buyback Program - Stock Titan
ICON plc Stock Takes Center Stage. What’s Next? - StocksToTrade
ICON plc’s Market Surge: Examining Strong Moves - timothysykes.com
ICON plc Emerges as Phase 1 Clinical Trials Leader in New Benchmark Report - StocksToTrade
Icon Plc (ICLR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.15%
자본화:
|
볼륨(24시간):